Home

Silo Pharma, Inc. - Common Stock (SILO)

0.7010
+0.0154 (2.25%)
NASDAQ · Last Trade: Oct 2nd, 7:28 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.6856
Open0.7000
Bid0.6873
Ask0.7000
Day's Range0.6601 - 0.7051
52 Week Range0.4101 - 3.370
Volume569,705
Market Cap69.17M
PE Ratio (TTM)-0.6676
EPS (TTM)-1.1
Dividend & YieldN/A (N/A)
1 Month Average Volume2,630,941

Chart

About Silo Pharma, Inc. - Common Stock (SILO)

Silo Pharma Inc is a biotechnology company focused on leveraging psychedelic compounds and their therapeutic potential to treat various mental health conditions and neurological disorders. By researching and developing innovative drug delivery methods and formulations, the company aims to create effective treatments that can address unmet medical needs in the psychiatric space. Silo Pharma emphasizes collaboration with academic institutions and industry partners to advance its clinical programs and contribute to the evolving landscape of mental health therapies. Read More

News & Press Releases

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exercisable upon issuance and will expire five years from the effective date of a registration statement registering for resale the shares of common stock underlying the warrants.
By Silo Pharma, Inc. · Via GlobeNewswire · October 1, 2025
Stay updated with the stocks that are on the move in today's pre-market session.chartmill.com
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · September 30, 2025
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that will be immediately exercisable upon issuance and will expire five years from the effective date of a registration statement registering for resale the shares of common stock underlying the warrants. The closing of the offering is expected to occur on or about October 1, 2025, subject to the satisfaction of customary closing conditions.
By Silo Pharma, Inc. · Via GlobeNewswire · September 30, 2025
Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date
By Silo Pharma, Inc. · Via GlobeNewswire · September 29, 2025
These stocks are gapping in today's sessionchartmill.com
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · September 23, 2025
Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
Highly secure, institutional-grade infrastructure supports Bitcoin, Ethereum and Solana treasury strategy
By Silo Pharma, Inc. · Via GlobeNewswire · September 23, 2025
EXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Securitybenzinga.com
Silo Pharma partners with Fireblocks to secure its crypto treasury platform using multi-layer enterprise security and governance standards.
Via Benzinga · September 23, 2025
These stocks are moving in today's pre-market sessionchartmill.com
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · September 16, 2025
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives
By Silo Pharma, Inc. · Via GlobeNewswire · September 16, 2025
3 Under-the-Radar Biotechs Under $5 That Could Soar 200%marketbeat.com
3 biotech stocks under $5 with cancer, obesity, and psychedelic therapies offer speculative investors high-risk, high-reward potential: HOTH, SILO, and ANIX.
Via MarketBeat · September 9, 2025
Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
SARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that the Japan Patent Office has granted patent number 7683882 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress,” exclusively licensed to Silo by Columbia University. Columbia University recently received an Australian patent for the same invention.
By Silo Pharma, Inc. · Via GlobeNewswire · September 9, 2025
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University.
By Silo Pharma, Inc. · Via GlobeNewswire · September 3, 2025
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancersbenzinga.com
Hoth Therapeutics reported strong preclinical efficacy and safety data for HT-KIT, a precision antisense therapy targeting KIT-driven cancers.
Via Benzinga · September 2, 2025
Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
Manuscript featured in leading open-access scientific journal Alzheimer’s Research & Therapy
By Silo Pharma, Inc. · Via GlobeNewswire · August 21, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · August 19, 2025
Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
SPC-15’s intranasal spray formulation meets safety standards for clinical trial development
By Silo Pharma, Inc. · Via GlobeNewswire · August 19, 2025
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration
By Silo Pharma, Inc. · Via GlobeNewswire · August 5, 2025
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced completion of dosing in a U.S. Food and Drug Administration (FDA)-requested 7-day safety and toxicology large animal study of its lead asset SPC-15, and bioanalytical and safety/toxicology results for such study are expected within 60 days.
By Silo Pharma, Inc. · Via GlobeNewswire · July 16, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expects SPC-15 PTSD Study Results Within 90 Days
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced it expects data from two key preclinical studies of its lead candidate SPC-15 within 30 to 90 days. SPC-15 is an intranasal prophylactic designed to boost stress resilience and prevent Post-Traumatic Stress Disorder (PTSD). The ongoing studies include IND-enabling GLP-compliant toxicology and toxicokinetic testing, as well as a large animal safety study requested by the FDA. Results will inform a planned IND application, potentially before year-end, with a Phase 1 clinical trial anticipated in 2026. Silo aims to pursue the FDA’s 505(b)(2) pathway to expedite development of the therapy, which represents a novel approach in a field that has seen no new FDA drug approvals for PTSD in nearly 25 years.
Via Investor Brand Network · July 7, 2025
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved
By Silo Pharma, Inc. · Via GlobeNewswire · July 7, 2025
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
NEW YORK - June 25th, 2025 - Silo Pharma, Inc. ( Nasdaq: SILO ) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.
Via Get News · June 25, 2025
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University
By Silo Pharma, Inc. · Via GlobeNewswire · June 25, 2025
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
SILO Pharma (NASDAQ: SILO) today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease.
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives USPTO Notice of Allowance for PTSD Treatment Patent
Silo Pharma (NASDAQ: SILO) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its licensed patent application related to biomarkers for evaluating prophylactic treatments for stress-induced affective disorders. The patent, set to be issued as U.S. Patent No. 12,329,726 on June 17, 2025, bolsters Silo’s intellectual property around its lead candidate SPC-15, an intranasal PTSD treatment licensed from Columbia University. CEO Eric Weisblum emphasized the importance of this NIH-backed patent as the company prepares SPC-15 for Phase 1 clinical trials.
Via Investor Brand Network · June 11, 2025
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders”) that Silo licenses from Columbia University. 
By Silo Pharma, Inc. · Via GlobeNewswire · June 11, 2025